医学
荟萃分析
甲状腺癌
内科学
甲状腺
相对风险
置信区间
子群分析
激素
激素疗法
肿瘤科
癌症
泌尿科
乳腺癌
作者
Sohyun Park,Ji-In Bang,Keunyoung Kim,Youngduk Seo,Ari Chong,Chae Moon Hong,Dong‐Eun Lee,Miyoung Choi,Sang Woo Lee,So Won Oh
出处
期刊:Clinical Nuclear Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2024-01-19
标识
DOI:10.1097/rlu.0000000000005022
摘要
Background This meta-analysis and systematic review aimed to evaluate the therapeutic efficacy and advantages associated with the use of recombinant human thyroid-stimulating hormone (rhTSH) for radioactive iodine (RAI) therapy in patients with intermediate- to high-risk differentiated thyroid cancer. Patients and Methods MEDLINE, EMBASE, and Cochrane databases were searched to identify relevant articles reporting clinical outcomes of rhTSH compared with thyroid hormone withdrawal (THW) in patients with intermediate- to high-risk differentiated thyroid cancer published between January 2012 and June 2023. Meta-analyses were performed (PROSPERO registration number: CRD42022340915) to assess the success rate of radioiodine remnant ablation (RRA) in patients with intermediate to high risk and determine the disease control rate among patients with distant metastases, evaluated using the RECIST criteria. Results Thirteen studies involving 1858 patients were included in the meta-analysis. Pooled analyses revealed significantly higher overall RRA success rate in the rhTSH group compared with the THW group, with a risk ratio (RR) of 1.12 (95% confidence interval [CI], 1.01–1.25). However, in the subgroup analysis of high-risk patients, pooled analyses showed no significant differences in RRA success rate between the rhTSH group compared with the THW group with a pooled RR of 1.05 (95% CI, 0.88–1.24). In patients with distant metastases, there were no significant differences in the disease control rate between groups, with a pooled RR of 1.06 (95% CI, 0.78–1.44). Conclusions rhTSH for RAI therapy is a practical option for RAI therapy in patients with intermediate- to high-risk thyroid cancer, including those with distant metastases.
科研通智能强力驱动
Strongly Powered by AbleSci AI